These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6114373)

  • 1. During one year's neuroleptic treatment in rats striatal dopamine receptor blockade decreases but serum prolactin levels remain elevated.
    Dyer RG; Murugaiah K; Theodorou A; Clow A; Jenner P; Marsden CD
    Life Sci; 1981 Jan; 28(2):167-74. PubMed ID: 6114373
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Nature; 1979 Mar; 278(5699):59-61. PubMed ID: 570253
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
    Rupniak N; Hong M; Mansfield S; Fleminger S; Dyer R; Jenner P; Marsden CD
    Eur J Pharmacol; 1983 Sep; 93(3-4):195-200. PubMed ID: 6139285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of penfluridol on circling behavior and striatal DOPAC and serum prolactin concentrations in the rat.
    Annunziato LA; Wuerthele SM; Moore KE
    Eur J Pharmacol; 1978 Aug; 50(3):187-92. PubMed ID: 567584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged inhibition of striatal dopamine receptor sites by isofloxythepin.
    Lau YS; Runice C
    Eur J Pharmacol; 1985 Oct; 116(1-2):25-31. PubMed ID: 2865162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat.
    Scavone C; De Lucia R; Bernardi MM; Aizenstein ML
    Eur J Pharmacol; 1985 May; 112(1):11-6. PubMed ID: 4040467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Eur J Pharmacol; 1980 May; 63(2-3):135-44. PubMed ID: 6103813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
    Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
    Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor blocking action of a dibenzothiepin derivative isofloxythepin in rats.
    Yamada K; Matsuo N; Nagashima M; Kumagai M; Furukawa T
    Clin Exp Pharmacol Physiol; 1989 Feb; 16(2):109-16. PubMed ID: 2565774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 13. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum.
    Murugaiah K; Theodorou A; Mann S; Clow A; Jenner P; Marsden CD
    Nature; 1982 Apr; 296(5857):570-2. PubMed ID: 6122161
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE; Grabowska-Andén M
    Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol.
    Morgan DG; Sinha YN; Finch CE
    Neuroendocrinology; 1984 May; 38(5):407-10. PubMed ID: 6728123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
    Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.